Arvinas’ (ARVN) “Overweight” Rating Reiterated at Cantor Fitzgerald

Arvinas (NASDAQ:ARVN)‘s stock had its “overweight” rating reiterated by equities researchers at Cantor Fitzgerald in a research note issued to investors on Friday,Benzinga reports.

Other analysts also recently issued research reports about the company. BTIG Research assumed coverage on Arvinas in a research report on Tuesday, December 10th. They issued a “buy” rating and a $69.00 price objective for the company. Oppenheimer decreased their target price on Arvinas from $50.00 to $40.00 and set an “outperform” rating on the stock in a report on Thursday, October 31st. HC Wainwright reiterated a “buy” rating and issued a $87.00 price objective on shares of Arvinas in a research report on Wednesday, December 11th. Stephens started coverage on shares of Arvinas in a research note on Monday, November 18th. They issued an “overweight” rating and a $55.00 price objective on the stock. Finally, Barclays cut their price target on shares of Arvinas from $48.00 to $32.00 and set an “overweight” rating on the stock in a research report on Monday. One analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $61.45.

Arvinas Trading Up 1.0 %

NASDAQ:ARVN traded up $0.19 during mid-day trading on Friday, hitting $19.29. 473,505 shares of the company’s stock traded hands, compared to its average volume of 813,114. The firm has a 50 day moving average of $19.75 and a two-hundred day moving average of $23.67. The firm has a market capitalization of $1.33 billion, a price-to-earnings ratio of -4.14 and a beta of 1.88. Arvinas has a 12 month low of $16.61 and a 12 month high of $53.08.

Institutional Trading of Arvinas

Several institutional investors and hedge funds have recently bought and sold shares of ARVN. JPMorgan Chase & Co. raised its stake in Arvinas by 18.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,329,303 shares of the company’s stock worth $57,371,000 after purchasing an additional 367,343 shares in the last quarter. Baker BROS. Advisors LP acquired a new position in shares of Arvinas in the third quarter valued at approximately $9,989,000. SG Americas Securities LLC raised its position in Arvinas by 228.8% during the 4th quarter. SG Americas Securities LLC now owns 32,424 shares of the company’s stock worth $622,000 after purchasing an additional 22,564 shares during the last quarter. Wasatch Advisors LP boosted its stake in shares of Arvinas by 58.3% in the 3rd quarter. Wasatch Advisors LP now owns 435,943 shares of the company’s stock valued at $10,737,000 after purchasing an additional 160,510 shares during the last quarter. Finally, Barclays PLC increased its holdings in Arvinas by 198.9% in the third quarter. Barclays PLC now owns 121,699 shares of the company’s stock worth $2,998,000 after purchasing an additional 80,984 shares in the last quarter. Institutional investors own 95.19% of the company’s stock.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.